Skip to main content
. 2022 Sep 29;9(3):29–40. doi: 10.15586/jkcvhl.v9i3.243

Figure 1:

Figure 1:

Suggested sequences for second- and third-line treatment of clear-cell RCC.

Abbreviations: RCC, renal cell carcinoma; VEGFR, vascular endothelial growth factor receptor; TKI: tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor; Sun: sunitinib; Paz: pazopanib; Cabo, cabozantinib; Nivo, nivolumab; Ipi: ipilimumab; Pembro, pembrolizumab; Axi, axitinib; Tivo, tivozanib; Lenva, Lenvatinib; Eve, everolimus.